










Psychiatric visits during the postpartum year in women with eating disorders who continue or discontinue antidepressant treatment in pregnancy

Nhung T. H. Trinh PhD¹  | Birgitte Dige Semark MSc^{2,3}  |
Trine Munk-Olsen PhD^{2,4}  | Xiaoqin Liu PhD²  | Øyvind Rø MD, PhD^{5,6}  |
Cynthia M. Bulik PhD^{7,8,9}  | Leila Torgersen PhD¹⁰  | Angela Lupattelli PhD¹  |
Liselotte Vogdrup Petersen PhD² 

¹PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway

²NCRR—The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark

³CIRRAU—Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark

⁴Department of Clinical Research, University of Southern Denmark, Odense, Denmark

⁵Regional Department for Eating Disorders, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

⁶Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

⁷UNC Center of Excellence for Eating Disorders, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

⁸Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

⁹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

¹⁰Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway

Correspondence

Nhung T. H. Trinh, PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Norway. PO Box

Abstract

Objective: To determine the association between *continued* antidepressant use in pregnancy and postpartum psychiatric visits for eating (ED) or mood/anxiety disorders in women with preexisting ED.

Method: Using Danish health registry data (1998–2015), we identified 3529 pregnancies in women with ED prepregnancy: (i) 564 with *continued* antidepressant use before and during pregnancy; (ii) 778 with *discontinued* antidepressants before pregnancy; (iii) 2137 *unexposed*. Outpatient and inpatient postpartum visits for an ED or a mood/anxiety disorder constituted the outcome measures. We estimated hazard ratios (HRs) and 95% confidence intervals (CI) using Cox regression with inverse probability of treatment weighting, and performed stratified analyses by antidepressant prescription filling in the first 3 months postpartum.

Results: The weighted cumulative incidence for an ED visit at end of follow-up was 4.5% (*continued*) and 4.8% (*discontinued*). We found no association between *continued* antidepressant and postpartum ED visit, relative to *discontinued* (HR: 0.89, 95% CI: 0.52–1.52). The HR for postpartum mood/anxiety disorder visit was 1.27 (95% CI: 0.68–2.36) with *continued* antidepressants versus *discontinued* but decreased if more than two antidepressant prescriptions were refilled. *Continued* antidepressant use was associated with a 57% reduced likelihood of a postpartum ED visit versus *discontinued* use in pregnancies with antidepressant prescription refills in the early postpartum.

Conclusion: Among women with preexisting ED, there was no association between *continued* antidepressant use during pregnancy and the likelihood of postpartum psychiatric visits, relative to *discontinued* antidepressants before pregnancy. *Continuation* of treatment into the early postpartum is associated with reduced likelihood of postpartum ED visit.

Angela Lupattelli and Liselotte Vogdrup Petersen share last authorship.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *International Journal of Eating Disorders* published by Wiley Periodicals LLC.

1068 Blindern, 0316 Oslo, Norway.
Email: nhung.trinh@farmasi.uio.no

Funding information

Norges Forskningsråd, Grant/Award Number: 288696; NIMH, Grant/Award Numbers: R01MH118278, R01MH119084, R01MH124871, R01MH120170; Brain and Behavior Research Foundation Distinguished Investigator Grant; Swedish Research Council, Grant/Award Number: 538-2013-8864; Lundbeck Foundation, Grant/Award Number: R276-2018-4581; Marie Skłodowska-Curie grant, Grant/Award Number: 891079

Action Editor: B. Timothy Walsh

Public Significance: Based on data from the Danish registries, we identified 3529 pregnancies among women with preexisting eating disorders before pregnancy. Women with continued antidepressant treatment both before and during pregnancy did not have a lower probability of having postpartum psychiatric visits for an eating disorder or for mood/anxiety disorders (often coexisting with eating disorders), relative to those who discontinued antidepressants before pregnancy. Further continuation of antidepressant treatment into the early postpartum is associated with improved maternal postpartum outcomes. However, residual confounding by disease severity limits confidence in this conclusion.

KEYWORDS

antidepressant, eating disorders, postpartum, pregnancy, preventative effect

1 | INTRODUCTION

Eating disorders (EDs) are serious psychiatric disorders primarily affecting women of childbearing age, which often coexist with depression and anxiety (Hendrick, 2006; Hoek & van Hoeken, 2003). Clinical manifestations include both physical and psychological dysfunction caused by severe and persistent disturbance in eating behaviors and associated distressing thoughts and emotions. The perinatal period is a highly vulnerable time for women with EDs. The pregnancy-related changes in body shape may increase anxiety about weight gain, and the postpartum is a high-risk time for relapse of psychiatric disorders that often occur with EDs (Putnam et al., 2017; Viguera et al., 2011; Ward, 2008).

Data for broadly defined ED types have reported that 0.2% of pregnant women reported bulimia nervosa (BN), 4.8% binge-eating disorder (BED), 0.1% unspecified eating disorder purging type (EDNOS-P), and 0.1% anorexia nervosa (AN) (Bulik et al., 2007). Whereas pregnancy may represent a time of remission of some EDs (Bulik et al., 2007), the postpartum period often poses an elevated risk for depression and anxiety, greater use of psychotropic medications, and re-emergence of symptoms of disordered eating (Knoph et al., 2013; Lupattelli, Spigset, Torgersen, et al., 2015; Petterson et al., 2016).

Selective serotonin reuptake inhibitor (SSRI) antidepressants have been shown to be beneficial in treating BN in nonpregnant individuals, potentially because bulimic behaviors might be driven by serotonin dysregulation; efficacy data remain more uncertain for BED (Hendrick, 2006; Mitchell et al., 2013). Given the overlap in symptoms between EDs and depression/anxiety, these medications are often prescribed to women with EDs, including those who are pregnant (Davis & Attia, 2017). In our prior work, antidepressant use in pregnancy ranged from 2.8% in women with BED, to 5.6% in BN, and 13.0% in AN (Lupattelli, Spigset, Torgersen, et al., 2015). Pregnancy, however, remains a major driver for intentional discontinuation of a psychotropic medication or poor drug adherence (Lupattelli, Spigset, Bjornsdottir, et al., 2015; Petersen et al., 2011).

Limited evidence exists on the effectiveness of antidepressants in pregnancy or as a preventive treatment of postnatal mental illness in high-risk patients (Bayrampour et al., 2020; Liu et al., 2022;

Molyneaux et al., 2014; Sharma, 2017). The few available studies focus mainly on depression (Bayrampour et al., 2020). Treatment effectiveness in the context of EDs in population-based settings is largely unknown. Understanding the potential preventative effect of antidepressant treatment in pregnancy on relapse or worsening of the ED after childbirth is an important clinical question, as continuation of ED symptoms and/or onset of other mood or anxiety dimensions postpartum can negatively affect mother-child health and bonding, and the woman's ability to care for the child (Stein et al., 2014).

In a population sample of women diagnosed with ED before pregnancy, we investigated the association between antidepressant continuation in pregnancy and an ED or mood/anxiety disorder within the first year postpartum, relative to antidepressant discontinuation before pregnancy. To better address confounding by ED severity and psychiatric comorbidity, information regarding women diagnosed with an ED before pregnancy who did not receive a prescription for antidepressants before and during pregnancy acted as an additional comparator. We focused on the postpartum period because this is a time of significant relapse in the context of EDs and coexisting psychiatric disorders, and therefore we investigated the role of antidepressant use in the early postpartum on the associations of interest. We hypothesized that women treated with antidepressants during pregnancy would be less likely to have recorded visits for EDs or mood/anxiety disorders in the postpartum period compared with those who discontinued treatment before pregnancy.

2 | PARTICIPANTS

2.1 | Study design and population

We conducted a population-based cohort study using data from the Danish nationwide registries. Data from the Danish Civil Registration System (Erlangsen & Fedyszyn, 2015) (including all live births and residents in Denmark) were used to link the following registries via a unique personal identification number: (1) The Danish Medical Birth Registry, including compulsory medical records on all live births and stillbirths since 1973 (Bliddal et al., 2018); (2) the Danish National




FIGURE 1 Data flow to achieve the final study population. AD, antidepressants

Patient Register, including admission records to hospitals since 1977 and outpatient specialist health care since 1995 (Andersen et al., 1999); (3) the Danish National Prescription Registry (Kildemoes et al., 2011), capturing records on all prescriptions dispensed in Denmark since 1995; (4) the Danish Psychiatric Central Research Register (Mors et al., 2011), including records on all inpatient and specialist psychiatric encounters in Denmark since 1969. The Danish National Patient Register and the Danish Psychiatric Central Research Register contain diagnoses on all in- and outpatients coded according to the 10th version (ICD-10) from 1994 onwards (WHO, n.d.).

We identified 3529 singleton pregnancies resulting in live-births in 1998–2015, among women who had received at least one ED diagnosis (ICD-10 codes: F50.0–F50.9) in the 4-year period prior to the last menstrual period (LMP), as registered in the Psychiatric Central Research Register or the National Patient Register. We selected 4 years as a look-back time window as the course of EDs is often protracted (Eddy et al., 2017). The ED types were defined based on the first ED diagnosis registered in the period before pregnancy. The LMP date was estimated by subtracting gestational age from the date of birth, and gestational age was primarily based on ultrasound scan (Jørgensen, 1999). Additional exclusion criteria to reach the final study population are shown in Figure 1.

2.2 | Antidepressant exposure

We defined pregnancies as exposed to antidepressants when a woman filled at least one antidepressant prescription (ATC code N06A) either in the period between LMP and date of birth or in the 30 days prior to pregnancy with a number of dispensed defined daily doses (DDD) overlapping the pregnancy window. The 30-day window prior to LMP was chosen based on a prior validation study (Skurtveit et al., 2013). Women were considered exposed to antidepressants before pregnancy if at least one antidepressant prescription was filled at any time in the 2 years prior to pregnancy with dispensed DDDs not overlapping the LMP. The sensitivity and specificity of antidepressant prescriptions being filled in pregnancy versus self-report is moderate to high in Scandinavian countries (Olesen et al., 2001; Skurtveit et al., 2013). Antidepressants were divided into three groups: SSRIs (sertraline, fluoxetine, paroxetine, citalopram, escitalopram, fluvoxamine), serotonin–norepinephrine reuptake inhibitors (SNRIs, including venlafaxine and duloxetine) and others (including any antidepressant other than SSRI or SNRI).

Based on antidepressant prescriptions 2 years before LMP and during pregnancy, we classified the study population into four mutually exclusive groups: (1) *continued* antidepressant use ($n = 564$), that

is, having at least one antidepressant prescription filled both before and during pregnancy; (2) *discontinued* antidepressant use, that is, having antidepressant prescriptions filled only before pregnancy ($n = 778$); (3) *initiated* antidepressant in pregnancy, that is, having an antidepressant prescription filled only during pregnancy ($n = 50$); and (4) *unexposed*, that is, no antidepressant prescription filled either before or during pregnancy ($n = 2137$). To ensure that pregnancies had a common treatment history at baseline, our main comparison was between *continued* and *discontinued* antidepressants. To better understand the role of confounding by ED severity and psychiatric comorbidity, we also compared *continued* antidepressants versus *unexposed*. Only descriptive statistics are provided for antidepressant initiators due to small sample size.

2.3 | Outcome measures

The primary outcome was a postpartum ED, defined as having an outpatient or inpatient ED diagnosis (ICD-10 codes: F50.0-F50.9) in the period from delivery to end of first postpartum year, as retrieved from the Psychiatric Central Research Register or the Patient Register. Our secondary outcome was postpartum mood/anxiety, defined as a diagnosis of mood (ICD-10: F30-F39) and/or anxiety disorders (ICD-10: F40-F41) in the same period. We selected the specific diagnoses of mood/anxiety disorders given the high comorbidity of ED with these disorders (Baskin & Galligan, 2019; Braun et al., 1994; Micali et al., 2011).

2.4 | Measured confounders

We considered a set of potential confounders, including maternal age at pregnancy start, place of residence at delivery, employment, income, educational attainment 2 years before delivery, smoking status in pregnancy, parity and year of delivery. We also included (1) use of other medications in first trimester of pregnancy, that is, opioid analgesics (ATC code N02A), antiepileptics (ATC code N03A), antipsychotics (ATC code N05A), benzodiazepine/z-hypnotics (ATC codes: N05BA, N05CD, N05CF); and (2) proxies of maternal psychiatric history and environment, including inpatient psychiatric stays (ICD-10: F codes except F50.0, F50.1, F50.2, F50.3, F50.8, F50.9), paternal use of antidepressants in the period of 4 years prior to LMP, and familial psychiatric history (i.e., any psychiatric diagnosis in the National Patient Register or the Central Psychiatric Register in the parents of the mothers) any time prior to delivery. Other factors, for example, being born in Denmark (yes vs. no) were measured and presented descriptively across the exposure groups.

2.5 | Data analyses

To estimate the association between *continued* antidepressant use in pregnancy and the postpartum outcomes, we fit unadjusted and

weighted analyses using inverse probability of treatment weighting (IPTW), based on the propensity score (Austin & Stuart, 2015). Logistic regression models were first fitted to estimate the probability of “*continued* antidepressants” relative to “*discontinued*” or “*unexposed*”, given the set of confounders. To estimate hazard ratio (HR), we then fit unadjusted and weighted Cox regression models with robust standard errors, using time in days since delivery as the time scale. The follow-up period started at birth and ended on the date of the first event, 1 year postpartum, or emigration, whichever came first. We included unadjusted and weighted smoothed cumulative event curves for both outcomes (Hernan, 2010). For the mood/anxiety disorder outcome, the cumulative event curves of the exposure groups crossed, and therefore we split the follow-up time at 180 days postpartum, estimating period-specific HRs (Xu & O’Quigley, 2000). The splitting point was selected based on the weighted incidence curve (Figure 2). To better understand the role of duration of antidepressant treatment in pregnancy and minimize risk of misclassification of exposure, we replicated the main analyses by requiring at least two antidepressant prescriptions during pregnancy in the *continued* group. Results are shown as unadjusted and weighted HRs with corresponding 95% confidence intervals (CIs). All analyses and plots were conducted using R version 4.04 and R studio version 1.4.1106. Balance in the distribution of covariates before and after IPTW was checked via the “*cobalt*” package using standardized mean differences (Greifer, 2021).

Altogether, 13.6% of the pregnancies had missing values in at least one of the confounders. We imputed incomplete data via multiple imputations with chained equation (15 imputations with 20 iterations each), using the “*mice*” package (Moodie et al., 2008; Rubin, 1987; Sterne et al., 2009). Exposure and outcome variables, baseline hazard of the outcome, confounding, and auxiliary variables were included in the imputation model.

2.6 | Sensitivity and subanalyses

First, women with different ED types may have different responses to antidepressant treatment, and therefore the analyses were stratified by ED type: AN (ICD-10 codes 50.0-50.1), BN (ICD-10 codes 50.2-50.3), and ED not otherwise specified – EDNOS (ICD-10 codes 50.4-50.9). Second, because information on prepregnancy body mass index (BMI) was only available between 2003 and 2012 in the registry (leading to 54.6% missing values in our study population), we replicated the analysis in a subgroup of pregnancies with BMI information (i.e., complete case analysis) and adjusted for BMI in the models. As BMI data were missing at random, we did not conduct multiple imputations (Lupattelli et al., 2019). Third, we conducted a sensitivity analysis, including only the first pregnancy recorded during the study period. Fourth, to better understand whether the postpartum visit for ED was a new episode or follow-up encounter for the disorder, we replicated the analyses only in those women having no contact for ED or for mood/anxiety disorder during




FIGURE 2 Smoothed cumulative incidence for postpartum visit for ED (a (upper left), b (upper right), c (lower left), d (lower right)) and mood/anxiety disorders (panel c and d) by antidepressant exposure in pregnancy, unadjusted and weighted (the gray lines indicate the 95% confidence interval)

gestation. Fifth, antidepressant use in the postpartum period may influence the likelihood of having postpartum psychiatric visits. Our analysis comparing *continued* with *discontinued* antidepressants before pregnancy was stratified on whether the participant filled an antidepressant prescription in the first 3 months postpartum. Of note, study participants were classified as having filled antidepressant if the event of interest did not occur before the first prescription fill.

2.7 | Ethics

The study was approved by the Danish Data Protection Agency. No informed consent is required for purely register-based studies on the basis of anonymized data in accordance with the legislation in Denmark.

3 | RESULTS

There were 1,139,387 pregnancies registered in the 1998–2015 period in Denmark, of which 3529 fulfilled the inclusion criteria (Figure 1). Of these, 1059 (30.0%) had AN diagnosis, 1465 (41.5%) BN and 1005 (28.5%) EDNOS as first registered diagnosis in the four period before LMP. ED type switch was uncommon in the pre-pregnancy period (<19.1% of the pregnancies). We identified 778 women with prepregnancy ED (22.0%) with *discontinued* antidepressant use before pregnancy, 564 (16.0%) with *continued* use before and during, and 50 (1.4%) who *initiated* antidepressants during pregnancy. The remaining women were *unexposed* (60.6%) to antidepressants both before and during gestation. SSRIs were the most commonly prescribed antidepressants during pregnancy among women with prepregnancy ED (Table 1), and co-prescribing of more than one class of antidepressant was uncommon. Of 564 women

TABLE 1 Distribution of the eating disorder type and antidepressant use in pregnancy by exposure groups

	Unexposed to AD (n = 2137)	Discontinued AD (n = 778)	Continued AD (n = 564)	Initiated AD (n = 50)
Eating disorder type in the 4 years period before pregnancy ^a				
Anorexia nervosa	638 (29.9)	223 (28.7)	183 (32.4)	15 (30.0)
Bulimia nervosa	899 (42.1)	333 (42.8)	209 (37.1)	24 (48.0)
Eating disorder not otherwise specified	600 (28.1)	222 (28.5)	172 (30.5)	11 (22.0)
Antidepressant type used in pregnancy				
SSRIs	-	-	495 (87.8)	44 (88.0)
SNRIs	-	-	71 (12.6)	n/a
Other antidepressants	-	-	49 (8.7)	6 (12.0)
>1 antidepressant groups during pregnancy	-	-	50 (8.9)	n/a

Note: Data are expressed as n (%).

Abbreviations: AD, antidepressant; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitors; n/a, numbers cannot be presented due to too few observations.

^aEating disorder diagnoses are mutually exclusive.

with *continued* antidepressant use, 433 (76.8%) filled at least two prescriptions during pregnancy; 224 (39.7%) and 65 (11.5%) pregnancies were treated throughout the three trimesters or in both the first and second trimester, respectively, while 134 (23.8%) were treated only in the first trimester. Generally, the rates of antidepressant prescriptions decreased over time ($n = 440$ in first, $n = 364$ in second, and $n = 302$ in third trimester) among women with *continued* antidepressant use. Out of 564 women who continued antidepressants during pregnancy, 324 (57.4%) continued their treatment in the early postpartum.

Table 2 shows the characteristics of the study population by antidepressant exposure status in pregnancy. Most of the pregnancies were of women born in Denmark. Women with *continued* antidepressant use were slightly older than the other groups, but the average maternal age was younger than 30 years old across all groups. The distribution of confounders between the exposure groups was well-balanced after weighting (most standardized mean differences $<.1$) (Figures S1 and S2).

3.1 | Postpartum eating disorder

Figure 2 (panels a and b) shows the smoothed cumulative incidence for having a postpartum visit for ED by three groups. At 100 and 200 days postdelivery, the probability of an ED visit was 1.1% and 2.0% among *unexposed*, 1.5% and 3.0% among women with *continued* antidepressants, and 2.0% and 3.5% among those with *discontinued* antidepressants before pregnancy, respectively. At 1 year postpartum, the probability reached 4.5%–4.8% in the *continued* and *discontinued* groups and 3.6% in the *unexposed*. The *continued* antidepressants group had greater hazard of a postpartum ED visit relative to the *unexposed* group (weighted HR: 1.31, 95% CI: 0.79–2.19), but the 95% CI included the null (Table 3). This hazard was lower when the *discontinued* group served as the comparator

(weighted HR: 0.89, 95% CI: 0.52–1.52), and when exposure was defined as having at least two filled prescriptions during pregnancy (weighted HR: 0.91, 95% CI: 0.51–1.64), albeit the 95% CI included the null.

3.2 | Postpartum mood/anxiety disorders

Figure 2 (panels c and d) shows the smoothed cumulative incidence for having a postpartum visit for mood/anxiety disorders by exposure groups. Women with *continued* antidepressant use during pregnancy had the lowest incidence of this outcome in the first half of the postpartum year, relative to both those who *discontinued* antidepressants and *unexposed*; thereafter, at about 180 days since delivery, the incidence rate of *continued* and *discontinued* antidepressant groups began to converge. When the hazard was averaged over the study follow-up, pregnancies with *continued* antidepressant use had a 27% increased risk of having a postpartum visit for mood/anxiety disorders compared with the *discontinued* group, but the 95% CI included the null and was imprecise (Table 3). The period-specific analysis (Table S1) indicates a somewhat lower hazard (HR: 0.90–0.95) with *continued* antidepressants relative to both comparators after weighting, but the 95% CI included the null.

3.3 | Sensitivity analyses

The association measures between *continued* antidepressant use in pregnancy and maternal postpartum outcomes by type of ED (Table 4) generally aligned with the findings in the total population (Table 3). The sensitivity analyses also adjusted for BMI yielded slightly lower point estimates than the main analyses (Table S2). Results restricted to the first pregnancies (Table S3) or to those having no ED or mood/anxiety contact during pregnancy (Table S4), generally aligned with the main

TABLE 2 Characteristics of the study population by antidepressant exposure group

	Unexposed to AD (n = 2137)	Discontinued AD (n = 778)	Continued AD (n = 564)	Initiated AD (n = 50)
Maternal sociodemographics				
Age at conception (years); mean (SD)	27.0 (4.9)	26.6 (4.1)	28.3 (5.0)	25.5 (5.1)
BMI at conception; ^a mean (SD)	21.9 (4.8)	22.0 (5.3)	22.7 (5.2)	21.8 (5.8)
Missing	1099 (51.4)	366 (47.0)	237 (42.0)	21 (42.0)
Primiparity	1303 (61.0)	535 (68.8)	347 (61.5)	31 (62.0)
Missing	37 (1.7)	22 (2.8)	12 (2.1)	na
Marital status				
Married or cohabiting	1408 (65.9)	435 (55.9)	334 (59.2)	31 (62.0)
Single, divorced or widowed	708 (33.1)	343 (44.1)	230 (40.8)	19 (38.0)
Missing	21 (1.0)	-	-	-
Attained educational level ^b				
Lower than university/college	1558 (72.9)	640 (82.3)	425 (75.4)	na
University/college	555 (26.0)	130 (16.7)	126 (22.3)	
Missing	24 (1.1)	8 (1.0)	13 (2.3)	
Maternal income ^b				
Quintile 1	407 (19.0)	178 (22.9)	90 (16.0)	14 (28.0)
Quintile 2	633 (29.6)	230 (29.6)	160 (28.4)	12 (24.0)
Quintile 3	489 (22.9)	194 (24.9)	176 (31.2)	12 (24.0)
Quintile 4	388 (18.2)	120 (15.4)	92 (16.3)	6 (12.0)
Quintile 5	213 (10.0)	56 (7.2)	46 (8.2)	6 (12.0)
Missing	7 (0.3)	-	na	-
Occupation ^b				
Employed	936 (43.8)	291 (37.4)	227 (40.2)	na
Unemployed or missing	51 (2.4)	15 (1.9)	10 (1.8)	
Outside labor force	497 (23.3)	246 (31.6)	199 (35.3)	
Student	653 (30.6)	226 (29.0)	128 (22.7)	
Smoking during pregnancy	468 (21.9)	210 (27.0)	161 (28.5)	14 (28.0)
Missing	53 (2.5)	25 (3.2)	20 (3.5)	na
Calendar year of delivery				
1998–2002	430 (20.1)	137 (17.6)	53 (9.4)	6 (12.0)
2003–2006	479 (22.4)	158 (20.3)	107 (19.0)	19 (38.0)
2007–2011	586 (27.4)	232 (29.8)	214 (37.9)	14 (28.0)
2002–2015	642 (30.0)	251 (32.3)	190 (33.7)	11 (22.0)
Place of residence at delivery ^c				
Capital	479 (22.4)	157 (20.2)	109 (19.3)	na
Suburb of the capital	307 (14.4)	93 (12.0)	83 (14.7)	
Larger municipalities	353 (16.5)	132 (17.0)	113 (20.0)	
Smaller municipalities	547 (25.6)	209 (26.9)	142 (25.2)	
Other municipalities in Denmark or missing	451 (21.1)	187 (24.0)	117 (20.8)	
Born in Denmark	1923 (90.0)	724 (93.1)	521 (92.4)	44 (88.0)
Maternal mental health				
Maternal psychiatric history ^d	522 (24.4)	252 (32.4)	262 (46.5)	11 (22.0)
Familial psychiatric history ^e	469 (21.9)	199 (25.6)	118 (20.9)	12 (24.0)
Missing	117 (5.5)	32 (4.1)	32 (5.7)	na
Inpatient psychiatric treatment ^d	260 (12.2)	223 (28.7)	205 (36.3)	13 (26.0)
Outpatient psychiatric treatment ^d	895 (41.9)	518 (66.6)	441 (78.2)	35 (70.0)

TABLE 2 (Continued)

	Unexposed to AD (n = 2137)	Discontinued AD (n = 778)	Continued AD (n = 564)	Initiated AD (n = 50)
Dispensing of other medications in first trimester				
Benzodiazepines/z-hypnotics	14 (0.7)	27 (3.5)	31 (5.5)	na
Antipsychotics	8 (0.4)	15 (1.9)	41 (7.3)	na
Antiepileptics	15 (0.7)	9 (1.2)	20 (3.5)	-
Opioid analgesics	27 (1.3)	20 (2.6)	18 (3.2)	na
Paternal mental health and child characteristics				
Paternal psychiatric history (yes) ^f (yes); n (%)	232 (10.9)	108 (13.9)	96 (17.0)	10 (20.0)
Missing	75 (3.5)	24 (3.1)	21 (3.7)	na
Paternal antidepressant use (yes) ^f	149 (7.0)	77 (9.9)	81 (14.4)	6 (12.0)
Missing	75 (3.5)	24 (3.1)	21 (3.7)	x ²
Infant sex (male)	1082 (50.6)	415 (53.3)	305 (54.1)	26 (52.0)
Gestational age; mean (SD)	276.8 (12.9)	276.3 (14.7)	273.5 (14.6)	274.0 (15.5)
Preterm birth	147 (6.9)	58 (7.5)	58 (10.3)	na

Note: Data are expressed as n (%) unless otherwise specified.

Abbreviation: na, numbers cannot be presented due to too few observations.

^aBMI only available for births between 2003 and 2012.

^bMeasured 2 years before conception.

^cLarger size municipality includes towns with more than 100,000 inhabitants, while smaller municipalities include those with 10,000–100,000 inhabitants.

^dIndicates history in the 4 years prior to LMP.

^eIndicates history any time prior to delivery.

^fIndicates psychiatric treatment or filled prescriptions in the period from 4 years before pregnancy until LMP.

TABLE 3 Associations of continued antidepressant in pregnancy with postpartum visits for eating disorders, mood and/or anxiety disorders

Antidepressant use during pregnancy	No	Events	IR per 1000 person years	Unadjusted HR (95% CI)	Weighted ^a HR (95% CI)	Unadjusted HR (95% CI)	Weighted ^a HR (95% CI)
Eating disorder visit							
Unexposed	2137	73	95	Reference	Reference	-	-
Discontinued	778	36	130	1.37 (0.92, 2.03)	1.20 (0.77, 1.65)	Reference	Reference
Continued	564	26	130	1.36 (0.86, 2.14)	1.31 (0.79, 2.19)	1.00 (0.60, 1.67)	0.89 (0.52, 1.52)
Continued, ≥2 AD fills	433	21	137	1.43 (0.87, 2.25)	1.41 (0.80, 2.50)	1.05 (0.61, 1.82)	0.91 (0.51, 1.64)
Mood and/or anxiety disorder visit							
Unexposed	2137	26	34	Reference	Reference	-	-
Discontinued	778	22	79	2.35 (1.33, 4.14)	2.20 (1.18, 4.13)	Reference	Reference
Continued	564	25	124	3.71 (2.17, 6.34)	2.03 (0.74, 5.61)	1.58 (0.89, 2.79)	1.27 (0.68, 2.36)
Continued, ≥2 AD fill	433	16	103	3.08 (1.68, 5.64)	2.12 (0.75, 6.00)	1.31 (0.69, 2.49)	0.99 (0.49, 2.02)

Abbreviations: AD, antidepressant; CI, confidence interval; HR, hazard ratio; IR, incidence rate.

^aWeighted with stabilized inverse probability of treatment weighting (IPTW) using the defined set of covariates.

analysis with *continued* antidepressants relative to *discontinued*. We observed different results upon stratification by antidepressant filled prescription status in the first 3 months postpartum. Among women who had an antidepressant prescription filled in the first 3 months postpartum, the likelihood of having a postpartum visit for ED was 57% lower among those with *continued* antidepressants compared to *discontinued* (weighted HR: 0.43, 95% CI: 0.19, 0.99) (Table S5). However, this likelihood was 59%–114% higher with *continued* versus *discontinued* antidepressants among those women who did not have an antidepressant prescription filled in the first 3 months postpartum. The likelihood

of having a postpartum visit for mood/anxiety disorders with *continued* antidepressants was consistent with the main results, regardless of whether the study participants filled antidepressant prescription in the first 3 months after delivery.

4 | DISCUSSION

This nationwide, population-based study reports no reduced risk for an ED visit in the postpartum year with *continued* antidepressant use

TABLE 4 Associations of continued antidepressant in pregnancy with postpartum visits for eating disorders, mood and/or anxiety disorders, by eating disorder type prior to pregnancy start^a

Antidepressant use during pregnancy	No	Unadjusted HR (95% CI)	Weighted HR (95% CI) ^b	Unadjusted HR (95% CI)	Weighted HR (95% CI) ^b
Pregnancies within women with bulimia nervosa					
Eating disorder visit					
Unexposed	899	Reference	Reference	-	-
Discontinued	333	1.87 (1.01, 3.47)	1.71 (0.86, 3.38)	Reference	Reference
Continued	209	2.10 (1.04, 4.25)	1.72 (0.78, 3.79)	1.12 (0.52, 2.42)	0.95 (0.42, 2.16)
Mood and/or anxiety disorder visit					
Unexposed	899	Reference	Reference	-	-
Discontinued	333	-	-	Reference	Reference
Continued	209	4.33 (1.54, 12.17)	4.50 (1.52, 13.35)	1.36 (0.46, 4.04)	1.78 (0.54, 5.87)
Pregnancies within women with anorexia nervosa ^c					
Eating disorder visit					
Unexposed	638	Reference	Reference	-	-
Discontinued	223	0.92 (0.46, 1.84)	0.84 (0.38, 1.84)	Reference	Reference
Continued	183	0.78 (0.34, 1.77)	0.67 (0.28, 1.61)	0.85 (0.32, 2.22)	0.98 (0.37, 2.63)
Pregnancies within women with eating disorder not otherwise specified					
Eating disorder visit					
Unexposed	600	Reference	Reference	-	-
Discontinued	222	1.44 (0.64, 3.22)	0.93 (0.39, 2.19)	Reference	Reference
Continued	172	1.46 (0.61, 3.51)	1.30 (0.44, 3.81)	1.02 (0.38, 2.71)	0.76 (0.27, 2.12)
Mood and/or anxiety visit					
Unexposed	600	Reference	Reference	-	-
Discontinued	222	3.03 (1.24, 7.43)	3.19 (1.24, 8.23)	Reference	Reference
Continued	172	6.86 (3.06, 15.36)	6.76 (2.27, 20.11)	2.27 (1.05, 4.91)	1.85 (0.80, 4.29)

Abbreviations: CI, confidence interval; HR, hazard ratio.

^aEating disorder types are mutually exclusive.

^bWeighted with stabilized inverse probability of treatment weighting (IPTW) using the defined set of covariates.

^cNo data can be shown for mood and/or anxiety disorders for women with anorexia nervosa due to small cell count.

in pregnancy relative to *discontinued* antidepressants before pregnancy. In absolute terms, the probability of a visit for an ED among the *continued* and *discontinued* antidepressant groups was low (1.5% and 2.0%, respectively) in the early postpartum, but increased to 4.5% and 4.9% at 1 year postpartum. Upon stratification by filled antidepressant prescriptions in the 3 months postpartum, we found a moderately reduced likelihood of a postpartum visit for an ED with *continued* antidepressants relative to *discontinued*, but only among those women who filled antidepressant prescriptions in the early postpartum period. Antidepressant continuation in pregnancy alone may not be sufficient to reduce the risk of distal postpartum mental health outcomes; further treatment continuation into the early postpartum may be necessary to improve outcomes. We did not observe a reduction in likelihood of having postpartum visit for mood and/or anxiety with *continued* antidepressants in pregnancy; this finding remained consistent in the stratified analysis by filled antidepressant prescriptions in the 3 months postpartum. This study also documents that severity of the ED and other psychiatric conditions around the time of pregnancy initiation is possibly a key confounder, as the

comparison with *unexposed* pregnancies inflated our effect estimates (Simon et al., 2015). A more appropriate comparator, such as the *discontinued* antidepressant group in the current study, produces less biased point estimates for antidepressant continuation (Wood et al., 2018). It is important to note that this study examined selected postpartum mental health outcomes and whether outcomes could be improved by antidepressant treatment in pregnancy. Hence, the benefit of antidepressant treatment on patient-reported mental health in the context of pregnancy and/or for other psychiatric dimensions (e.g., obsessive-compulsive disorders) postpartum, remains a topic for future research.

Understanding the effect of pharmacological interventions for ED during pregnancy in population-based setting is methodologically challenging as few women initiate treatment, and information on time-varying symptom severity is often lacking (Robins et al., 2000; Swanson et al., 2015). One additional challenge is that women with an ED who succeed in conceiving may represent a selected group of women at the healthier end of the ED severity spectrum, especially in patients with AN. Similarly, those seeking treatment for an ED

constitute only a portion of the whole population cases (Hart et al., 2011). The lack of a definite benefit of *continued* antidepressant use in pregnancy versus *discontinued* antidepressants on postpartum visit for ED was consistent across comparisons, and decreased only slightly after adjusting for prepregnancy BMI. Thus, antenatal use of antidepressants, either directly or indirectly via improving maternal symptomatology during pregnancy, does not seem to favor distal selected mental health outcomes after childbirth. Treatment continuation in the early postpartum may be necessary to improve maternal mental health outcomes. Yet, it is important to note that the starting and stopping scenarios of antidepressant exposure from prepregnancy to end of gestation are complex (Bandoli et al., 2018; Charlton et al., 2015; Lupattelli et al., 2018), and that in many cases, antidepressant treatment may be interrupted or switched, or medication dosage may be reduced to levels that may be ineffective for the individual woman (Lupattelli et al., 2018; Swanson et al., 2015; Yonkers et al., 2011). Indeed, only 4 in 10 pregnancies with *continued* antidepressants in this study maintained treatment across all three trimesters, and 26% were treated only in the first trimester. About 43% of those continuing antidepressants during pregnancy did not further continue their treatment in the early postpartum.

Pharmacological treatment of EDs remains an underdeveloped field of research (Mitchell et al., 2013). The limited available data in nonpregnant individuals with AN suggest that fluoxetine, an SSRI antidepressant, is not efficacious treatment of AN in the underweight state or after weight restoration (Kaye et al., 1991; Walsh et al., 2006). This aligns with our findings, albeit few women in our study population had AN. In women with BN, there was no association of antidepressant continuation in pregnancy on postpartum ED visit. This is somewhat surprising as SSRI efficacy in BN has been reported in randomized clinical trials (RCT) (Bacaltchuk & Hay, 2003). Multiple factors could explain this finding: (1) the distribution and metabolism of SSRI may differ in pregnant women than nonpregnant participants in RCTs; (2) the efficacy of SSRIs in RCTs on remission for binge episodes is negligible (13% risk reduction) (Bacaltchuk & Hay, 2003), and this effect size is undetectable in our study given the small sample size; (3) women with BN who continue or initiate antidepressants in pregnancy are also those with the most severe course, and therefore at greater risk for postpartum relapse despite pharmacotherapy (Knoph et al., 2013; Lupattelli, Spigset, Torgersen, et al., 2015); (4) since the effective dose of SSRIs for BN is higher than for some other disorders (Bacaltchuk & Hay, 2003), inadequate antidepressant dose-adjustment during gestation (Schoresanis et al., 2020), or patient-initiated dose reductions due to concerns of harmful drug effects on the unborn child (Petersen et al., 2015), may reduce their benefit.

The temporal trend for the lower risk in the first half of the postpartum year followed by higher risk thereafter for postpartum mood/anxiety diagnoses with *continued* versus *discontinued* antidepressant requires careful interpretation (Herman, 2010). It could be argued that pregnancies with *discontinued* antidepressants are more susceptible to onset of mood and/or anxiety episodes soon after delivery, relative to women who were taking antidepressants during gestation. At the same time, the apparently elevated probability may simply reflect quicker

contact by the women with their healthcare providers to resume treatment (Trinh et al., 2022), particularly if treatment discontinuation was driven by fear of adverse antidepressant effects on the unborn child (Petersen et al., 2015). However, antidepressants are mostly prescribed by general practitioners in Nordic countries. The heightened risk of a postpartum visit for mood and/or anxiety observed only when the *unexposed* group acted as a comparator, suggests that severity of an ED around the time of pregnancy initiation may be a key confounder in psychotropic drug research (Wood et al., 2018).

The decision-making process about antidepressant treatment during pregnancy is complex, as it involves weighing the possible risk of exposure in utero against the potential adverse effects of suboptimally treated maternal ED to both the mother and child. In utero exposure to EDs per se increases the risk of a spectrum of negative health outcomes in both women and their offspring (Linna et al., 2014; Micali et al., 2012; Watson et al., 2017). Although there is increasing evidence that antidepressant exposure does not substantially increase the risk of negative immediate and long-term outcomes in children (Spigset & Nordeng, 2016), further research is needed on the potential benefits and risk of continuing treatment with antidepressants in pregnancy, specifically in women with EDs.

4.1 | Strengths and limitations

One strength is that our study is population-based, covering the entire population of women in Denmark presenting with ED before and/or during pregnancy. By including only pregnancies in women having an underlying ED (Hernan et al., 2008; Wood et al., 2018), we minimized confounding by indication; this approach partially removes unmeasured confounding by factors related to EDs, and affords a fairer comparison of health outcomes across exposure groups. To minimize the risk of measured confounding, we used inverse probability treatment weighting methods including a vast array of maternal sociodemographic factors, co-medication, proxy of psychiatric severity, familial psychiatric history, and partner's use of antidepressants. However, we cannot rule out that residual and/or unmeasured confounding by ED severity and other maternal factors influenced our results.

Some limitations require consideration. We used national registry data, which limits our ability to assess whether a filled antidepressant prescription coincides with actual use, as well as prescribed dose adjustments and intensity of use during pregnancy (Bandoli et al., 2018). However, redefinition of exposure as at least two filled antidepressant prescriptions during pregnancy did not change our conclusions, and there is good agreement between antidepressant prescription filled and self-report (sensitivity = 66.9% and specificity = 99.7%) for Norwegian data (Olesen et al., 2001; Skurtveit et al., 2013). We could not verify whether the indication for antidepressant treatment was the ED or another comorbid psychiatric disorder (e.g., depression or anxiety) nor if the patient received any nonpharmacological care. Granular data on time-varying symptom severity for the ED and comorbid conditions are not captured in our data, leading to residual confounding. The

small sample impeded the detection of small effect sizes, to examine associations by individual antidepressant classes or substances, and to consider ED switch or more severe outcomes such as hospitalization for ED. As EDs are defined based on ICD-10 diagnostic criteria, we were unable to correctly identify the disorder under the ED not otherwise specified category. We based the ED type classification on the first ED diagnosis recorded in the 4 years pre-pregnancy; however, ED type crossover was uncommon in the pre-pregnancy period. In addition, inclusion criteria and outcome measures are based on inpatient and outpatient ICD-10 diagnoses. The small sample size prevented more granular characterization of comorbid psychiatric disorders prior to pregnancy. We also acknowledge that the reliance on ICD-10 diagnoses to characterize ED and mood/anxiety symptoms does not allow us to estimate antidepressant effectiveness from a dimensional perspective or include measures of symptom severity. Consultations at private practices without public subsidies were not captured in registry data. However, use of private care in the Nordic countries is uncommon. Women with EDs seeking treatment and thereby receiving a diagnosis represent only a small proportion of the total population cases (Hart et al., 2011), which limits generalizability of the findings. We cannot rule out the possibility that a postpartum visit for an ED may influence women's subsequent mood; however, if it exists, this correlation is not differential by antidepressant use during pregnancy. This is supported by our findings showing that the HRs for postpartum ED visits do not align with those for mood/anxiety disorders and very few study participants had recorded postpartum visits for both outcomes. However, we also acknowledge that in situations where the ED and mood/anxiety disorders co-occur, the clinician may report the diagnosis that best represents the presenting problems. Our study relies on Danish registry-linkage data, and the vast majority of the study population was born in Denmark. Generalization of our study findings to other settings and populations should be done with caution.

5 | CONCLUSION

In this population-based study among women with a preexisting ED, *continued* antidepressant treatment during pregnancy was not associated with reduced likelihood of having postpartum visit for ED or mood/anxiety disorder, relative to *discontinued* treatment before pregnancy. These findings do not preclude a possible benefit of antidepressants in pregnancy on maternal antenatal mental health and/or for other psychiatric dimensions postpartum. Given confounding by disease severity, we cannot rule out the benefit of antidepressant continuation in pregnancy. Continuation of antidepressant treatment both during pregnancy and the early postpartum was associated with a moderately reduced likelihood of postpartum visit for ED, but not on mood/anxiety disorder, highlighting the importance of continuity of treatment to improve outcomes. This is only a first step in producing the evidence base for pharmacological treatment decisions among pregnant women with EDs.

AUTHOR CONTRIBUTIONS

Nhung Trinh: Investigation; methodology; validation; writing – original draft; writing – review and editing. **Birgitte Dige Semark:** Data curation; formal analysis; investigation; methodology; software; validation; visualization. **Trine Munk-Olsen:** Investigation; methodology; validation; writing – review and editing. **Xiaoqin Liu:** Investigation; methodology; validation; writing – review and editing. **Øyvind Rø:** Investigation; methodology; validation; writing – review and editing. **Cynthia Marie Bulik:** Investigation; methodology; validation; writing – review and editing. **Leila Torgersen:** Investigation; methodology; validation; writing – review and editing. **Angela Lupattelli:** Conceptualization; funding acquisition; investigation; methodology; project administration; resources; supervision; validation; visualization; writing – original draft; writing – review and editing. **Liselotte Petersen:** Conceptualization; investigation; methodology; supervision; validation; visualization; writing – review and editing.

FUNDING INFORMATION

Nhung Trinh and Angela Lupattelli, and the research project, are supported by the Norwegian Research Council (grant no. 288696). Cynthia Marie Bulik is supported by NIMH (R01MH120170; R01MH124871; R01MH119084; R01MH118278); Brain and Behavior Research Foundation Distinguished Investigator Grant; Swedish Research Council (Vetenskapsrådet, award: 538-2013-8864); Lundbeck Foundation (grant no. R276-2018-4581). Xiaoqin Liu is supported by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 891079. No other relationships or activities that could appear to have influenced the submitted work.

CONFLICT OF INTEREST

CM Bulik reports: Shire (grant recipient, Scientific Advisory Board member); Lundbeckfonden (grant recipient); Pearson (author, royalty recipient); Equip Health Inc. (Clinical Advisory Board). The authors have no conflict of interest to declare. We affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of any organization or company.

DATA AVAILABILITY STATEMENT

The data in this project were delivered by the registry holders to the researchers as pseudonymized data files. Data are available upon request to the registry holders, provided legal and ethical approvals.

ORCID

Nhung T. H. Trinh  <https://orcid.org/0000-0003-2794-5322>
 Birgitte Dige Semark  <https://orcid.org/0000-0002-1250-7066>
 Trine Munk-Olsen  <https://orcid.org/0000-0002-0786-7147>
 Xiaoqin Liu  <https://orcid.org/0000-0003-4519-1536>
 Øyvind Rø  <https://orcid.org/0000-0002-1936-1960>
 Cynthia M. Bulik  <https://orcid.org/0000-0001-7772-3264>

Leila Torgersen  <https://orcid.org/0000-0002-3416-5941>
 Angela Lupattelli  <https://orcid.org/0000-0002-8787-3183>
 Liselotte Vogdrup Petersen  <https://orcid.org/0000-0002-0479-5379>

REFERENCES

- Andersen, T. F., Madsen, M., Jørgensen, J., Mellekjær, L., & Olsen, J. H. (1999). The Danish National Hospital Register. A valuable source of data for modern health sciences. *Danish Medical Bulletin*, 46(3), 263–268.
- Austin, P. C., & Stuart, E. A. (2015). Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Statistics in Medicine*, 34(28), 3661–3679. <https://doi.org/10.1002/sim.6607>
- Bacaltchuk, J., & Hay, P. (2003). Antidepressants versus placebo for people with bulimia nervosa. *Cochrane Database of Systematic Reviews*, 2003(4), Cd003391. <https://doi.org/10.1002/14651858.cd003391>
- Bandoli, G., Kuo, G. M., Sugathan, R., Chambers, C. D., Rolland, M., & Palmsten, K. (2018). Longitudinal trajectories of antidepressant use in pregnancy and the postnatal period. *Archives of Women's Mental Health*, 16, 411–419. <https://doi.org/10.1007/s00737-018-0809-2>
- Baskin, R., & Galligan, R. (2019). Disordered eating and the perinatal period: A systematic review and best evidence synthesis of mental health and psychosocial correlates. *European Eating Disorders Review*, 27(5), 462–480. <https://doi.org/10.1002/erv.2675>
- Bayrampour, H., Kapoor, A., Bunka, M., & Ryan, D. (2020). The risk of relapse of depression during pregnancy after discontinuation of antidepressants: A systematic review and meta-analysis. *The Journal of Clinical Psychiatry*, 81(4), 19r13134. <https://doi.org/10.4088/JCP.19r13134>
- Bliedall, M., Broe, A., Pottegård, A., Olsen, J., & Langhoff-Roos, J. (2018). The Danish medical birth register. *European Journal of Epidemiology*, 33(1), 27–36. <https://doi.org/10.1007/s10654-018-0356-1>
- Braun, D. L., Sunday, S. R., & Halmi, K. A. (1994). Psychiatric comorbidity in patients with eating disorders. *Psychological Medicine*, 24(4), 859–867. <https://doi.org/10.1017/S0033291700028956>
- Bulik, C. M., Von Holle, A., Hamer, R., Berg, C. K., Torgersen, L., Magnus, P., Stoltenberg, C., Siega-Riz, A. M., Sullivan, P., & Reichborn-Kjennerud, T. (2007). Patterns of remission, continuation and incidence of broadly defined eating disorders during early pregnancy in the Norwegian Mother and Child Cohort Study (MoBa). *Psychological Medicine*, 37(8), 1109–1118. <https://doi.org/10.1017/S0033291707000724>
- Charlton, R. A., Jordan, S., Pierini, A., Garne, E., Neville, A. J., Hansen, A. V., Gini, R., Thayer, D., Tingay, K., Puccini, A., Bos, H. J., Nybo Andersen, A. M., Sinclair, M., Dolk, H., & de Jong-van den Berg, L. (2015). Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: A population-based study in six European regions. *BJOG: An International Journal of Obstetrics and Gynaecology*, 122(7), 1010–1020. <https://doi.org/10.1111/1471-0528.13143>
- Davis, H., & Attia, E. (2017). Pharmacotherapy of eating disorders. *Current Opinion in Psychiatry*, 30(6), 452–457.
- Eddy, K. T., Tabri, N., Thomas, J. J., Murray, H. B., Keshaviah, A., Hastings, E., Edkins, K., Krishna, M., Herzog, D. B., Keel, P. K., & Franko, D. L. (2017). Recovery from anorexia nervosa and bulimia nervosa at 22-year follow-up. *The Journal of Clinical Psychiatry*, 78(2), 184–189. <https://doi.org/10.4088/JCP.15m10393>
- Erlangsen, A., & Fedyszyn, I. (2015). Danish nationwide registers for public health and health-related research. *Scandinavian Journal of Public Health*, 43(4), 333–339. <https://doi.org/10.1177/1403494815575193>
- Greifer, N. (2021). Covariate Balance Tables and Plots: A Guide to the cobalt Package. <https://cran.r-project.org/web/packages/cobalt/vignettes/cobalt.html>
- Hart, L. M., Granillo, M. T., Jorm, A. F., & Paxton, S. J. (2011). Unmet need for treatment in the eating disorders: A systematic review of eating disorder specific treatment seeking among community cases. *Clinical Psychology Review*, 31(5), 727–735.
- Hendrick, V. (2006). *Psychiatric disorders in pregnancy and the postpartum: Principles and treatment*. Humana Press.
- Hernan, M. A. (2010). The hazards of hazard ratios. *Epidemiology*, 21(1), 13–15. <https://doi.org/10.1097/EDE.0b013e3181c1ea43>
- Hernan, M. A., Alonso, A., Logan, R., Grodstein, F., Michels, K. B., Willett, W. C., Manson, J. E., & Robins, J. M. (2008). Observational studies analyzed like randomized experiments: An application to postmenopausal hormone therapy and coronary heart disease. *Epidemiology*, 19(6), 766–779. <https://doi.org/10.1097/EDE.0b013e3181875e61>
- Hoek, H. W., & van Hoeken, D. (2003). Review of the prevalence and incidence of eating disorders. *The International Journal of Eating Disorders*, 34(4), 383–396. <https://doi.org/10.1002/eat.10222>
- Jørgensen, F. S. (1999). Epidemiological studies of obstetric ultrasound examinations in Denmark 1989–1990 versus 1994–1995. *Acta Obstetrica et Gynecologica Scandinavica*, 78(4), 305–309. <https://doi.org/10.1080/j.1600-0412.1999.780406.x>
- Kaye, W. H., Weltzin, T. E., Hsu, L. K., & Bulik, C. M. (1991). An open trial of fluoxetine in patients with anorexia nervosa. *The Journal of Clinical Psychiatry*, 52(11), 464–471.
- Kildemoes, H. W., Sørensen, H. T., & Hallas, J. (2011). The Danish National Prescription Registry. *Scandinavian Journal of Public Health*, 39(7 Suppl), 38–41. <https://doi.org/10.1177/1403494810394717>
- Knoph, C., Von Holle, A., Zerwas, S., Torgersen, L., Tambs, K., Stoltenberg, C., Bulik, C., & Reichborn-Kjennerud, T. (2013). Course and predictors of maternal eating disorders in the postpartum period. *The International Journal of Eating Disorders*, 46(4), 355–368. <https://doi.org/10.1002/eat.22088>
- Linna, M. S., Raevuori, A., Haukka, J., Suvisaari, J. M., Suokas, J. T., & Gissler, M. (2014). Pregnancy, obstetric, and perinatal health outcomes in eating disorders. *American Journal of Obstetrics and Gynecology*, 211(4), 392.e1–e8. <https://doi.org/10.1016/j.ajog.2014.03.067>
- Liu, X., Molenaar, N., Agerbo, E., Momen, N. C., Rommel, A. S., Lupattelli, A., Bergink, V., & Munk-Olsen, T. (2022). Antidepressant discontinuation before or during pregnancy and risk of psychiatric emergency in Denmark: A population-based propensity score-matched cohort study. *PLoS Medicine*, 19(1), e1003895. <https://doi.org/10.1371/journal.pmed.1003895>
- Lupattelli, A., Spigset, O., Bjørnsdottir, I., Hämeen-Anttila, K., Mårdbj, A.-C., Panchaud, A., Juraski, R. G., Rudolf, G., Odalovic, M., Drozd, M., Twigg, M. J., Juch, H., Moretti, M. E., Kennedy, D., Rieutord, A., Zagorodnikova, K., Passier, A., & Nordeng, H. (2015). Patterns and factors associated with low adherence to psychotropic medications during pregnancy—A cross-sectional, multinational web-based study. *Depression and Anxiety*, 32(6), 426–436. <https://doi.org/10.1002/da.22352>
- Lupattelli, A., Spigset, O., Torgersen, L., Zerwas, S., Hatle, M., Reichborn-Kjennerud, T., Bulik, C. M., & Nordeng, H. (2015). Medication use before, during, and after pregnancy among women with eating disorders: A study from the Norwegian mother and child cohort study. *PLoS One*, 10(7), e0133045. <https://doi.org/10.1371/journal.pone.0133045>
- Lupattelli, A., Wood, M., Ystrom, E., Skurtveit, S., Handal, M., & Nordeng, H. (2018). Effect of time-dependent selective serotonin reuptake inhibitor antidepressants during pregnancy on behavioral, emotional, and social development in preschool-aged children. *Journal of the American Academy of Child and Adolescent Psychiatry*, 57(3), 200–208. <https://doi.org/10.1016/j.jaac.2017.12.010>
- Lupattelli, A., Wood, M. E., & Nordeng, H. (2019). Analyzing missing data in perinatal pharmacoepidemiology research: Methodological considerations to limit the risk of bias. *Clinical Therapeutics*, 41(12), 2477–2487. <https://doi.org/10.1016/j.clinthera.2019.11.003>
- Micali, N., De Stavola, B., dos-Santos-Silva, I., Graaff, J. S.-d., Jansen, P. W., Jaddoe, V. W. V., Hofman, A., Verhulst, F. C., Steegers, E. A. P., & Tiemeier, H. (2012). Perinatal outcomes and gestational weight gain in women with eating disorders: A population-based cohort study. *BJOG An International Journal of Obstetrics and Gynaecology*, 119(12), 1493–1502. <https://doi.org/10.1111/j.1471-0528.2012.03467.x>

- Micali, N., Simonoff, E., & Treasure, J. (2011). Pregnancy and post-partum depression and anxiety in a longitudinal general population cohort: The effect of eating disorders and past depression. *Journal of Affective Disorders*, 131(1–3), 150–157. <https://doi.org/10.1016/j.jad.2010.09.034>
- Mitchell, J. E., Roerig, J., & Steffen, K. (2013). Biological therapies for eating disorders. *The International Journal of Eating Disorders*, 46(5), 470–477. <https://doi.org/10.1002/eat.22104>
- Molyneaux, E., Howard, L. M., McGeown, H. R., Karia, A. M., & Trevillion, K. (2014). Antidepressant treatment for postnatal depression. *Cochrane Database of Systematic Reviews*, (9), CD002018. <https://doi.org/10.1002/14651858.CD002018.pub2>
- Moodie, E. E., Delaney, J. A., Lefebvre, G., & Platt, R. W. (2008). Missing confounding data in marginal structural models: A comparison of inverse probability weighting and multiple imputation. *International Journal of Biostatistics*, 4(1), Article 13. <https://doi.org/10.2202/1557-4679.1106>
- Mors, O., Perto, G. P., & Mortensen, P. B. (2011). The Danish psychiatric central research register. *Scandinavian Journal of Public Health*, 39(7 Suppl), 54–57. <https://doi.org/10.1177/1403494810395825>
- Olesen, C., Sondergaard, C., Thrane, N., Nielsen, G. L., de Jong-van den Berg, L., & Olsen, J. (2001). Do pregnant women report use of dispensed medications? *Epidemiology*, 12(5), 497–501.
- Petersen, I., Gilbert, R. E., Evans, S. J., Man, S. L., & Nazareth, I. (2011). Pregnancy as a major determinant for discontinuation of antidepressants: An analysis of data from The Health Improvement Network. *The Journal of Clinical Psychiatry*, 72(7), 979–985. <https://doi.org/10.4088/JCP.10m06090blu>
- Petersen, I., McCrea, R. L., Lupattelli, A., & Nordeng, H. (2015). Women's perception of risks of adverse fetal pregnancy outcomes: A large-scale multinational survey. *BMJ Open*, 5(6), e007390. <https://doi.org/10.1136/bmjopen-2014-007390>
- Pettersson, C. B., Zandian, M., & Clinton, D. (2016). Eating disorder symptoms pre- and postpartum. *Archives of Women's Mental Health*, 19(4), 675–680. <https://doi.org/10.1007/s00737-016-0619-3>
- Putnam, K. T., Wilcox, M., Robertson-Blackmore, E., Sharkey, K., Bergink, V., Munk-Olsen, T., Deligiannidis, K. M., Payne, J., Altamus, M., Newport, J., Apter, G., Devouche, E., Viktorin, A., Magnusson, P., Penninx, B., Buist, A., Bilszta, J., O'Hara, M., Stuart, S., ... Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium. (2017). Clinical phenotypes of perinatal depression and time of symptom onset: Analysis of data from an international consortium. *Lancet Psychiatry*, 4(6), 477–485. [https://doi.org/10.1016/S2215-0366\(17\)30136-0](https://doi.org/10.1016/S2215-0366(17)30136-0)
- Robins, J. M., Hernan, M. A., & Brumback, B. (2000). Marginal structural models and causal inference in epidemiology. *Epidemiology*, 11(5), 550–560. <https://doi.org/10.1097/00001648-200009000-00011>
- Rubin, D. B. (1987). *Multiple imputation for nonresponse in surveys*. Wiley.
- Schoresanitis, G., Spigset, O., Stingl, J. C., Deligiannidis, K. M., Paulzen, M., & Westin, A. A. (2020). The impact of pregnancy on the pharmacokinetics of antidepressants: A systematic critical review and meta-analysis. *Expert Opinion on Drug Metabolism & Toxicology*, 16(5), 431–440. <https://doi.org/10.1080/17425255.2020.1750598>
- Sharma, V. (2017). A closer look at the preventative effect of antidepressants in postpartum depression. *Archives of Women's Mental Health*, 20(2), 357–360. <https://doi.org/10.1007/s00737-016-0709-2>
- Simon, G. E., Rossom, R. C., Beck, A., Waitzfelder, B. E., Coleman, K. J., Stewart, C., Operskalski, B., Penfold, R. B., & Shortreed, S. M. (2015). Antidepressants are not overprescribed for mild depression. *The Journal of Clinical Psychiatry*, 76(12), 1627–1632. <https://doi.org/10.4088/JCP.14m09162>
- Skurtveit, S., Selmer, R., Tverdal, A., Furu, K., Nystad, W., & Handal, M. (2013). Drug exposure: Inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations. *Journal of Clinical Epidemiology*, 66(9), 964–972. <https://doi.org/10.1016/j.jclinepi.2013.02.011>
- Spigset, O., & Nordeng, H. (2016). Safety of psychotropic drugs in pregnancy and breastfeeding. In E. Spina & G. Trifirò (Eds.), *Pharmacovigilance in psychiatry* (pp. 299–319). Springer International Publishing. https://doi.org/10.1007/978-3-319-24741-0_15
- Stein, A., Pearson, R. M., Goodman, S. H., Rapa, E., Rahman, A., McCallum, M., Howard, L. M., & Pariante, C. M. (2014). Effects of perinatal mental disorders on the fetus and child. *Lancet*, 384(9956), 1800–1819. [https://doi.org/10.1016/S0140-6736\(14\)61277-0](https://doi.org/10.1016/S0140-6736(14)61277-0)
- Sterne, J. A., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009). Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. *BMJ*, 338, b2393. <https://doi.org/10.1136/bmj.b2393>
- Swanson, S. A., Hernandez-Diaz, S., Palmsten, K., Mogun, H., Olfson, M., & Huybrechts, K. F. (2015). Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. *Pharmacoepidemiology and Drug Safety*, 24(9), 934–942. <https://doi.org/10.1002/pds.3798>
- Trinh, N. T. H., Nordeng, H. M. E., Bandoli, G., Eberhard-Gran, M., & Lupattelli, A. (2022). Antidepressant and mental health care utilization in pregnant women with depression and/or anxiety: An interrupted time-series analysis. *Journal of Affective Disorders*, 308, 458–465. <https://doi.org/10.1016/j.jad.2022.04.101>
- Viguera, A. C., Tondo, L., Koukopoulos, A. E., Reginaldi, D., Lepri, B., & Baldessarini, R. J. (2011). Episodes of mood disorders in 2,252 pregnancies and postpartum periods. *The American Journal of Psychiatry*, 168(11), 1179–1185. <https://doi.org/10.1176/appi.ajp.2011.11010148>
- Walsh, B. T., Kaplan, A. S., Attia, E., Olmsted, M., Parides, M., Carter, J. C., Pike, K. M., Devlin, M. J., Woodside, B., Roberto, C. A., & Rockert, W. (2006). Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. *Journal of the American Medical Association*, 295(22), 2605–2612. <https://doi.org/10.1001/jama.295.22.2605>
- Ward, V. B. (2008). Eating disorders in pregnancy. *BMJ*, 336(7635), 93–96. <https://doi.org/10.1136/bmj.39393.689595.BE>
- Watson, H. J., Zerwas, S., Torgersen, L., Gustavson, K., Diemer, E. W., Knudsen, G. P., Reichborn-Kjennerud, T., & Bulik, C. M. (2017). Maternal eating disorders and perinatal outcomes: A three-generation study in the Norwegian Mother and Child Cohort Study. *Journal of Abnormal Psychology*, 126(5), 552–564. <https://doi.org/10.1037/abn0000241>
- WHO International statistical classification of diseases and related health problems 10th revision. <http://apps.who.int/classifications/icd10/browse/2015/en>
- Wood, M. E., Lapane, K. L., van Gelder, M., Rai, D., & Nordeng, H. M. E. (2018). Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control. *Pharmacoepidemiology and Drug Safety*, 27(2), 140–147. <https://doi.org/10.1002/pds.4336>
- Xu, R., & O'Quigley, J. (2000). Estimating average regression effect under non-proportional hazards. *Biostatistics*, 1(4), 423–439. <https://doi.org/10.1093/biostatistics/1.4.423>
- Yonkers, K. A., Gotman, N., Smith, M. V., Forray, A., Belanger, K., Brunetto, W. L., Lin, H., Burkman, R. T., Zelop, C. M., & Lockwood, C. J. (2011). Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? *Epidemiology*, 22(6), 848–854. <https://doi.org/10.1097/EDE.0b013e3182306847>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Trinh, N. T. H., Semark, B. D., Munk-Olsen, T., Liu, X., Rø, Ø., Bulik, C. M., Torgersen, L., Lupattelli, A., & Petersen, L. V. (2023). Psychiatric visits during the postpartum year in women with eating disorders who continue or discontinue antidepressant treatment in pregnancy. *International Journal of Eating Disorders*, 56(3), 582–594. <https://doi.org/10.1002/eat.23877>